K. Altundag And O. Altundag, "Superiority of letrozole over tamoxifen in the first-line treatment of metastatic breast cancer patients with normal serum HER-2/neu levels: question of tamoxifen resistance," JOURNAL OF CLINICAL ONCOLOGY , vol.21, no.24, pp.4656, 2003
Altundag, K. And Altundag, O. 2003. Superiority of letrozole over tamoxifen in the first-line treatment of metastatic breast cancer patients with normal serum HER-2/neu levels: question of tamoxifen resistance. JOURNAL OF CLINICAL ONCOLOGY , vol.21, no.24 , 4656.
Altundag, K., & Altundag, O., (2003). Superiority of letrozole over tamoxifen in the first-line treatment of metastatic breast cancer patients with normal serum HER-2/neu levels: question of tamoxifen resistance. JOURNAL OF CLINICAL ONCOLOGY , vol.21, no.24, 4656.
Altundag, K, And O Altundag. "Superiority of letrozole over tamoxifen in the first-line treatment of metastatic breast cancer patients with normal serum HER-2/neu levels: question of tamoxifen resistance," JOURNAL OF CLINICAL ONCOLOGY , vol.21, no.24, 4656, 2003
Altundag, K And Altundag, O. "Superiority of letrozole over tamoxifen in the first-line treatment of metastatic breast cancer patients with normal serum HER-2/neu levels: question of tamoxifen resistance." JOURNAL OF CLINICAL ONCOLOGY , vol.21, no.24, pp.4656, 2003
Altundag, K. And Altundag, O. (2003) . "Superiority of letrozole over tamoxifen in the first-line treatment of metastatic breast cancer patients with normal serum HER-2/neu levels: question of tamoxifen resistance." JOURNAL OF CLINICAL ONCOLOGY , vol.21, no.24, p.4656.
@article{article, author={K Altundag And author={O Altundag}, title={Superiority of letrozole over tamoxifen in the first-line treatment of metastatic breast cancer patients with normal serum HER-2/neu levels: question of tamoxifen resistance}, journal={JOURNAL OF CLINICAL ONCOLOGY}, year=2003, pages={4656} }